Federal contract award
75N91020F00001
BASE:PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY&INTERMEDIATE BIOMARKERS TASK ORDER: TARGETING STAT3 TO PREVENT HEPATOCELLULAR CARCINOMA (HCC) ASSOCIATED WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NIH NCI |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | 75N91019D00021 |
| Set-aside | Not reported |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $840.8K |
| Current contract value | $840.8K |
| Potential contract value / ceiling | $840.8K |
| Start date | Jun 1, 2020 |
| Current end date | May 31, 2025 |
| Potential end date | May 31, 2025 |
| Latest award activity | Jun 2, 2025 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 2 of 2 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jun 2, 2025 | P00008 | $-2.7K | BASE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY & INTERMEDIATE BIOMARKERS TASK ORDER: TARGETING STAT3 TO PREVENT HEPATOCELLULAR CARCINOMA (HCC) ASSOCIATED WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) |
| Mar 12, 2025 | P00007 | $0 | BASE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY & INTERMEDIATE BIOMARKERS TASK ORDER: TARGETING STAT3 TO PREVENT HEPATOCELLULAR CARCINOMA (HCC) ASSOCIATED WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.